Search research articles
Contact Us
Filters
Showing results (241-250 of 1,124) with videos related to
Page
of 113
Sort By:
JAMA Oncology
|
October 17, 2018
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review
, Christopher Parker, Valerie Lewington, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
Matthew R Smith, Fred Saad, Blair Egerdie, et al.
Urology
|
September 11, 2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
Matthew R Smith, Richard J Cook, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer
Richard J Cook, Robert Coleman, Janet Brown, et al.
Targeted Oncology
|
November 23, 2019
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
Susan Feyerabend, Fred Saad, Nolen Joy Perualila, et al.
The Canadian Journal of Urology
|
March 22, 2005
Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients
Alvaro Ramirez, Paul Perrotte, Luc Valiquette, et al.
The Lancet. Oncology
|
February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal, Fred Saad, David Penson, et al.
Urology
|
July 1, 2014
Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy
Herbert James, Ilija Aleksic, Marc Nicolas Bienz, et al.
European Urology Open Science
|
October 12, 2020
Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise
Pedro Lopez, Dennis R Taaffe, Robert U Newton, et al.
European Urology
|
December 4, 2012
New and emerging therapies for bone metastases in genitourinary cancers
Philip J Saylor, Andrew J Armstrong, Karim Fizazi, et al.
Page
of 113
Search research articles
Search
Showing results (241-250 of 1,124) with videos related to
Sort By:
Page
of 113
JAMA Oncology
|
October 17, 2018
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review
, Christopher Parker, Valerie Lewington, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer
Matthew R Smith, Fred Saad, Blair Egerdie, et al.
Urology
|
September 11, 2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer
Matthew R Smith, Richard J Cook, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer
Richard J Cook, Robert Coleman, Janet Brown, et al.
Targeted Oncology
|
November 23, 2019
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study
Susan Feyerabend, Fred Saad, Nolen Joy Perualila, et al.
The Canadian Journal of Urology
|
March 22, 2005
Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients
Alvaro Ramirez, Paul Perrotte, Luc Valiquette, et al.
The Lancet. Oncology
|
February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal, Fred Saad, David Penson, et al.
Urology
|
July 1, 2014
Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy
Herbert James, Ilija Aleksic, Marc Nicolas Bienz, et al.
European Urology Open Science
|
October 12, 2020
Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise
Pedro Lopez, Dennis R Taaffe, Robert U Newton, et al.
European Urology
|
December 4, 2012
New and emerging therapies for bone metastases in genitourinary cancers
Philip J Saylor, Andrew J Armstrong, Karim Fizazi, et al.
Page
of 113